Search
gantenerumab
Investigational Alzheimer drug tested in dominantly inherited Alzheimer's disease with average follow up of 5 years.
Clinical significance:
- no evidence of cognitive benefit
- reduces amyldoid plaques & lowers CSF total tau & phosphorylated tau
Mechanism of action:
- targets A-beta (beta-amyloid)
Notes:
- phase III trials [2]
- gantenerumab did not meet primary endpoint of slowing clinical decline in early Alzheimer's disease [2]
- beta-amyloid removal also was lower than expected [2]
- Rooche announced plans to shut down all clinical trials of gantenerumab in early Alzheimer's disease because the drug had repeatedly failed to demonstrate a significant clinical benefit [3]
Interactions
drug adverse effects of anti-Alzheimer monoclonal antibody
Related
investigational therapies for treatment of Alzheimer's disease
General
anti-Alzheimer monoclonal antibody
References
- George J
Investigational Alzheimer's Drug Shows Effects in Inherited Early-Onset Disease
MedPage Today June 21,2021
https://www.medpagetoday.com/neurology/alzheimersdisease/93193
- Salloway S. et al.
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Nature Medicine (2021)
PMID: 34155411
https://www.nature.com/articles/s41591-021-01369-8
- Safety and Efficacy Study of Gantenerumab in Participants With Early
Alzheimer's Disease (AD)
https://www.clinicaltrials.gov/ct2/show/NCT03443973
https://www.clinicaltrials.gov/ct2/show/NCT03444870
- George J
Alzheimer's Agent Fails; Antiseizure Drug Use Rises; Stress and Post-COVID
Outcomes. News and commentary from the world of neurology and neuroscience.
MedPage Today November 15, 2022
https://www.medpagetoday.com/neurology/generalneurology/101764
- Steenhuysen J
Roche shutters most trials of Alzheimer's drug after failed trials.
Reuters. 2022. Nov 30.
https://www.reuters.com/business/healthcare-pharmaceuticals/roche-shutters-most-trials-alzheimers-drug-after-failed-trials-2022-12-01/